Research & Development: Page 10
-
Permission granted by AbbVie
What is a ‘cure,’ really? AbbVie’s Humira creator leaps into the next phase of medicine
AbbVie’s head of R&D cures has lofty ambitions to end diseases like HIV through a community of researchers that work as one.
By Michael Gibney • Nov. 19, 2024 -
Brad Penner/Imagn Images/Reuters
The Dodgers’ World Series run brought attention to a rare disease. Annexon is stepping up to the plate.
The company is looking to score an FDA nod for its investigational therapy that targets a molecule linked to Guillain-Barré syndrome and other autoimmune diseases.
By Alexandra Pecci • Nov. 19, 2024 -
Explore the Trendline➔
Getty Images
TrendlineOncology R&D
Cancer research remains a prime focus for the industry and often leads to pharma’s most impactful breakthroughs.
By PharmaVoice staff -
Erik S. Lesser via Getty Images
Why Merck rolled the dice on an ‘unbelievable’ early-stage brain cancer drug
Merck’s acquisition of Modifi Biosciences bucks common M&A trends in pharma.
By Kelly Bilodeau • Nov. 18, 2024 -
Getty Images
The first MASH drug could open the door for others — including GLP-1s
With only one approved drug on the market, companies like Inventiva Pharma are advancing MASH drugs and seeking a competitive edge.
By Amy Baxter • Nov. 18, 2024 -
Getty Images
Where are they now? 4 biotechs that soared then crashed during the pandemic
How Novavax and others have restructured and trudged forward after their COVID-era high.
By Meagan Parrish • Nov. 15, 2024 -
Getty Images
Pharma’s grip on cancer R&D is having unintended consequences
A pair of studies paint a complicated picture of funding and missed research opportunities.
By Alexandra Pecci • Nov. 12, 2024 -
Getty Images
Spravato is just the beginning in a new wave of depression meds
Psychiatry is getting more targeted as drugmakers develop a new range of treatments for depression.
By Meagan Parrish • Nov. 11, 2024 -
Jacob Bell/PharmaVoice
An RNAi renaissance is creating a new generation of startups
Pioneers like Alnylam Pharmaceuticals have led the RNA interference field for years. Now, a crop of young biotechs is building on that foundation by taking the drugmaking technology in new directions.
By Gwendolyn Wu • Nov. 7, 2024 -
Getty Images
A diabetes drug, twice rejected, stumbles again — but its developer persists
After multiple rejections, Lexicon Pharmaceuticals is inching toward an FDA decision date next month for its adjunct type 1 diabetes therapy.
By Amy Baxter • Nov. 6, 2024 -
Permission granted by Rallybio
Two former Alexion leaders fight through a tough market to maintain a rare disease biotech
Rallybio is headed into a mid-stage trial with enough cash through 2026, but the cyclical market has made the journey difficult.
By Michael Gibney • Nov. 5, 2024 -
Permission granted by Sernova
ProfileCEO with type 1 diabetes works to deliver ‘world’s first’ functional cure
Sernova’s technology helped type 1 diabetes patients achieve insulin independence in early- and mid-stage trials.
By Alexandra Pecci • Nov. 5, 2024 -
Getty Images
Pharma takes aim at a wily foe — the Epstein-Barr virus
The pernicious and widespread virus has been linked to a range of diseases including MS and long COVID.
By Kelly Bilodeau • Nov. 4, 2024 -
Spencer Platt / Staff via Getty Images
Pfizer’s quest for market share in the ‘high stakes battleground’ of oral GLP-1s
Pfizer’s second-to-market goals for its oral GLP-1 drugs underscore big opportunities in the space.
By Amy Baxter • Nov. 4, 2024 -
Getty Images
A sickle cell cure exists. But patients need more than just gene therapy.
Almost a year after two historic approvals, Pfizer is pulling a sickle cell disease treatment from the market, and the outlook for patients feels shakier.
By Alexandra Pecci • Nov. 1, 2024 -
Photo illustration: Industry Dive; Getty Images
PharmaVoice 1002024 PharmaVoice 100s: Cancer Care Visionaries
Leaders who envision a world without cancer through oncology innovation.
By Michael Gibney • Nov. 1, 2024 -
Getty Images
Big Pharma earnings hang hope on the next generation of blockbusters
Pfizer, J&J, Biogen and Novartis are banking on new products to make up for maturing blockbusters, but future growth is not guaranteed.
By Michael Gibney • Oct. 31, 2024 -
Photo illustration: Industry Dive; Getty Images
PharmaVoice 1002024 PharmaVoice 100s: Clinical Trial Pros
Experts raising the bar in clinical trial design and collaboration.
By Amy Baxter • Oct. 31, 2024 -
Getty Images
PharmaVoice 1002024 PharmaVoice 100s: Cell and Gene Therapy Pioneers
Leaders molding the cutting-edge cell and gene therapy field into tomorrow's cures.
By Michael Gibney • Oct. 30, 2024 -
Photo illustration: Industry Dive; Getty Images
PharmaVoice 1002024 PharmaVoice 100s: Rare Disease Warriors
Pharma pros driving drug development and access for patients with high unmet needs.
By Meagan Parrish • Oct. 29, 2024 -
Getty Images
Q&AHow AZ’s respiratory wins are ramping up for a bigger prize in COPD
As AstraZeneca builds up indications for Fasenra, an ongoing trial will determine whether the respiratory drug can make up for past stumbles in COPD.
By Michael Gibney • Oct. 29, 2024 -
Getty Images
On the front lines of the superbug war, new treatments can’t arrive soon enough
As antimicrobial resistance rises, researchers are running out of time to fight each new wave of superbugs. And the funding isn’t enough.
By Kelly Bilodeau • Oct. 28, 2024 -
Permission granted by Photo illustration: Industry Dive; Getty Images
PharmaVoice 1002024 PharmaVoice 100s: Biotech Pathfinders
Leaders solving biology's toughest puzzles and driving innovation forward.
By Michael Gibney • Oct. 23, 2024 -
Buda Mendes via Getty Images
Dengue is spreading and Sanofi is pulling the U.S. market’s only vaccine. What’s next?
As Sanofi prepares to halt production on its dengue vaccine in 2026, locally acquired infections in the U.S. are raising the alarm.
By Alexandra Pecci • Oct. 23, 2024 -
Metamorworks/ICON
Sponsored by ICONHow AI can manage the risks and costs of postmarketing requirements
PMRs are not new but drug developers can use AI to predict risk and manage costs earlier in studies.
By Alexandre Malouvier • Oct. 21, 2024 -
Permission granted by Parexel
Clinical staff that feel like ‘tech support’ — and other issues a CRO exec contends with
From tech-related challenges to an ongoing staffing crunch, Parexel’s CEO explains what the clinical trials industry is up against.
By Meagan Parrish • Oct. 18, 2024
Previous
